S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Forecast, Price & News

$8.63
+0.01 (+0.12%)
(As of 05:16 PM ET)
Compare
Today's Range
$8.47
$8.84
50-Day Range
$7.27
$9.00
52-Week Range
$5.26
$10.85
Volume
81,569 shs
Average Volume
90,785 shs
Market Capitalization
$228.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.6% Upside
$15.50 Price Target
Short Interest
Bearish
6.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Fennec Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$12,939 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.50) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

818th out of 986 stocks

Biological Products, Except Diagnostic Industry

133rd out of 163 stocks


FENC stock logo

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Fennec Pharma (FRX) Earnings Dates & Reports
Analyst Ratings for Fennec Pharmaceuticals
See More Headlines

FENC Price History

FENC Company Calendar

Last Earnings
5/11/2023
Today
6/09/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+79.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-23,710,000.00
Pretax Margin
-1,554.56%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
($0.10) per share

Miscellaneous

Free Float
23,501,000
Market Cap
$229.05 million
Optionable
Optionable
Beta
0.17

Key Executives

  • Mr. Rostislav Raykov (Age 42)
    Pres, CEO & Director
  • Mr. Robert C. Andrade (Age 43)
    Chief Financial Officer
  • Mr. Mark Gowland
    Controller
  • Mr. Lei Fang
    Pres of Pharstat Inc
  • Ms. Anne McKay (Age 64)
    Regulatory Consultant













FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year price objectives for Fennec Pharmaceuticals' shares. Their FENC share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's share price to reach $15.50 in the next year. This suggests a possible upside of 79.2% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2023?

Fennec Pharmaceuticals' stock was trading at $9.60 on January 1st, 2023. Since then, FENC shares have decreased by 9.9% and is now trading at $8.65.
View the best growth stocks for 2023 here
.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our FENC earnings forecast
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.02. The company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $1.88 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Solas Capital Management LLC (4.86%), DG Capital Management LLC (4.73%), Harbert Fund Advisors Inc. (1.77%), Gendell Jeffrey L (0.96%), AIGH Capital Management LLC (0.61%) and Tamarack Advisers LP (0.56%). Insiders that own company stock include Chris A Rallis, Robert Andrade and Rosty Raykov.
View institutional ownership trends
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $8.65.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $229.05 million and generates $1.53 million in revenue each year. The company earns $-23,710,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -